Do not inject more frequently than every 3 days
GLP-1 heartburn is no joke
Jansson-Lfmark, R., Hjorth, S., & Gabrielsson, J
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial
In parallel, health systems should consider commissioning large RWS to understand the full benefits of GLP-1s in routine use including outcomes in the many patients currently using these drugs out-of-pocket
Oral GLP-1 Drug Development Trends Enter a Rapid Growth Phase Currently, there are 84 oral small-molecule GLP-1 drug candidates in development worldwide, with 52 already in clinical stages